Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Cited by 604
Related Papers
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
|Molecular Cancer|2022|1.4k
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
|Journal of Hematology & Oncology|2022|178
Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
|Journal of Hematology & Oncology|2021|176
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
|Journal for ImmunoTherapy of Cancer|2022|153